HEMOFIL M

This brand name is authorized in Hong Kong, Turkey, South Africa

Active ingredients

The drug HEMOFIL M contains one active pharmaceutical ingredient (API):

1 Coagulation factor VIII UNII 839MOZ74GK - ANTIHEMOPHILIC FACTOR HUMAN

Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X (factor Xa). Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies. Read about Coagulation factor VIII

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
HEMOFIL M Solution for infusion	FDA, National Drug Code (US)	MPI, US: SPL/Old

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B02BD02	Coagulation factor VIII	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: HK	Department of Health Drug Office	Identifier(s): 21557
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8681429550097, 8681429550103
Country: ZA	Health Products Regulatory Authority	Identifier(s): T/30.3/0616, T/30.3/0617, T/30.3/0618